HTX 0.00% 0.1¢ healthlinx limited

HealthLinx LimitedABN 88 098 640 352576 Swan Street Richmond VIC...

  1. 872 Posts.
    HealthLinx Limited
    ABN 88 098 640 352
    576 Swan Street Richmond VIC 3121
    Telephone: +61 3 9208 4200 I Facsimile: +61 3 9208 4201
    www.healthlinx.com.au
    Positive Findings in South Korean Study for OvPlex™
    27th June 2012, Melbourne: HealthLinx Limited (ASX:HTX) announced today that preliminary analysis of 220 patient
    samples required for the pivotal Korean Food and Drug Administration (KFDA) study to obtain regulatory approvals for
    OvPlex™ in South Korea has shown a significant advantage over the use of CA125 alone.
    The samples were analysed for the five OvPlex™ biomarkers in a blind fashion by Seoul Clinical Laboratories (SCL) and
    the anonymous raw data was then used to generate an OvPlex™ probability score. Mosaic Medical Pty Ltd has acted as
    trial coordinators on behalf of Healthlinx and has maintained the anonymity of the sample collection until after analysis
    was complete. A new diagnostic algorithm generated from interim data collected from 742 patient samples from the
    ongoing OvPlex™ multinational trial was used to predict the status of the South Korean sample cohort. The interim
    analysis demonstrates that OvPlex™ provided a statistically significant advantage over the use of CA125 alone,
    particularly with respect to correctly classifying patients with benign gynaecological conditions. That is, the use of
    OvPlex™ reduced the number of false positive diagnoses when compared to CA125 alone. Final analysis of the Korean
    trial data will take place after completion of the current multinational OvPlex™ trial and implementation of the new
    diagnostic algorithm.
    “These interim results are very exciting. This is a further independent sample set that have been through the OvPlex™
    algorithm and again the fact that the OvPlex™ test delivered a statistically significant improvement over CA125 alone has
    been demonstrated” says Nick Gatsios, managing director. “Clearly the final results will be driven by the completion of the
    larger multi centre, multi national study but this is still very exciting and encouraging to see that OvPlex™ reduces the
    false positive rates significantly over CA125 alone.”
    The outcome of the trial will also be reviewed in detail by the Principal Investigator, Professor Byoung-Gie Kim of
    Samsung Medical Center. Upon its successful completion a formal submission to the KFDA will follow and SCL who are
    co-funding the study will obtain an exclusive license to distribute OvPlex™ in South Korea.
    The South Korean market for ovarian cancer diagnostics is approximately 250,000 tests annually with the disease
    experiencing approximately 15% annual growth. In 2004 ovarian cancer was not rated as one of the top 10 cancers,
    however in 2009 it ranked as the 7th most prevalent and it is predicted that it will be 4th most prevalent by 2015. This
    translates as a significant opportunity for HealthLinx and its partners.
 
watchlist Created with Sketch. Add HTX (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.